Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: Reactive hyperemia peripheral arterial tonometric study

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 369-374

  Kono, Yasushi ^a   Fukuda, Shota ^a   Shimada, Kenei ^b   Nakanishi, Koki ^b   Otsuka, Kenichiro ^b   Kubo, Tomoichiro ^a   Jissho, Satoshi ^a   Taguchi, Haruyuki ^a   Yoshikawa, Junichi ^c   Yoshiyama, Minoru ^b  

^a Osaka Ekisaikai Hospital   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Nishinomiya Watanabe Cardiovascular Center   (Japan)

Author keywords

Coronary artery disease; Microvascular function; Statin

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; ROSUVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; EARLY INTERVENTION; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PERIPHERAL MICROVASCULAR FUNCTION; QUANTITATIVE ANALYSIS; REACTIVE HYPEREMIA PERIPHERAL ARTERY TONOMETRY; TONOMETRY; BRACHIAL ARTERY; COMPARATIVE STUDY; DRUG EFFECTS; MANOMETRY; MICROVASCULATURE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; VASCULAR ENDOTHELIUM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRACHIAL ARTERY; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MANOMETRY; MICROVESSELS; MIDDLE AGED; PYRIMIDINES; QUINOLINES; SULFONAMIDES;

EID: 84877117528     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S44099     Document Type: Article

References (34)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307.
3. Kirmizis D, Papagianni A, Dogrammatzi F, et al. Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. J Atheroscler Thromb. 2010;17(12):1256-1265.
4. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21(11):1712-1719.
5. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95(5):1126-1131.
6. Nonogaki K, Suzuki M, Kanai N, Sumii M, Kaji T. Short-term effect of pitavastatin on the reactive hyperemic index in post-menopausal women with high levels in serum LDL-cholesterol. Int J Cardiol. 2011;150(2):227-228.
7. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104(4):376-379.
8. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003;93(9):e98-e103.
9. Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136-138.
10. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J. 2009;73(8):1466-1472.
11. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol. 2003;41(10):1761-1768.
12. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117(19):2467-2474.
13. Matsuzawa Y, Sugiyama S, Sugamura K, et al. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol. 2010;55(16):1688-1696.
14. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010;31(9):1142-1148.
15. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39(2):257-265.
16. Gokce N, Keaney JF Jr, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41(10):1769-1775.
17. Shimada K, Fukuda S, Maeda K, et al. Aromatherapy alleviates endothelial dysfunction of medical staff after night-shift work: preliminary observations. Hypertens Res. 2011;34(2):264-267.
18. Hijmering ML, Stroes ES, Pasterkamp G, Sierevogel M, Banga JD, Rabelink TJ. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis. 2001;157(2):369-373.
19. Hamburg NM, Palmisano J, Larson MG, et al. Relation of brachial and digital measures of vascular function in the community: the Framingham heart study. Hypertension. 2011;57(3):390-396.
20. Schnabel RB, Schulz A, Wild PS, et al. Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. Circ Cardiovasc Imaging. 2011;4(4):371-380.
21. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol. 2006;101(2):545-548.
22. Livalo® (pitavastatin) [prescribing information]. Tokyo, Japan: Kowa Company, Ltd; 2010.
23. Crestor® (rosuvastatin). [prescribing information]. Osaka, Japan: AstraZeneca; 2011.
24. Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004;24(10):1842-1847.
25. Jantzen F, Konemann S, Wolff B, et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. J Physiol Pharmacol. 2007;58(3):503-514.
26. Kim MC, Ahn Y, Jang SY, et al. Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. Korean J Intern Med. 2011;26(3):294-303.
27. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol. 2012;73(4):518-535.
28. Catapano AL. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol. 2012;10(2):257-267.
29. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009;53(4):323-330.
30. Yoshino S, Hamasaki S, Ishida S, et al. Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. J Atheroscler Thromb. 2011;18(5):403-412.
31. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin. 2011;27(8):1551-1562.
32. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41(6):1281-1286.
33. Wassmann S, Hilgers S, Laufs U, Bohm M, Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22(7):1208-1212.
34. Fukuda S, Shimada K, Maeda K, et al. Circadian variation in coronary flow velocity reserve and its relation to alpha1-sympathetic activity in humans. Int J Cardiol. 2012;157(2):216-220.